InvestSMART

Bod Australia Limited (ASX: BDA) - Announcements

Current share price for BDA : $0.270 0.005 (1.82%)+

ASX company news and announcements for Bod Australia Limited (BDA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Bod Australia Limited (BDA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Bod Australia Limited (BDA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Bod Australia Limited (BDA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Appendix 4E and Audited Financial Statements 31 Aug 2018 4:55PM $0.585 $0.270 fallen by 53.85%
- Appointment of Mr Stephen Thompson as Executive Director 21 Aug 2018 9:04AM $0.585 $0.270 fallen by 53.85%
- Appendix 3B 7 Aug 2018 5:03PM $0.505 $0.270 fallen by 46.53%
- Quarterly Report and Appendix 4C 31 Jul 2018 4:42PM $0.500 $0.270 fallen by 46%
- Results of General Meeting 24 Jul 2018 10:41AM $0.520 $0.270 fallen by 48.08%
- Bod commences Phase I Clinical trial 24 Jul 2018 8:58AM $0.510 $0.270 fallen by 47.06%
- Notice of Extraordinary General Meeting & Proxy Form 22 Jun 2018 12:01PM $0.600 $0.270 fallen by 55%
- Bod signs agreement with Symbion 5 Jun 2018 9:32AM $0.660 $0.270 fallen by 59.09%
- Ceasing to be a substantial holder 4 Jun 2018 4:26PM $0.660 $0.270 fallen by 59.09%
- Becoming a substantial holder 4 Jun 2018 2:13PM $0.635 $0.270 fallen by 57.48%
- Appointment of Executive Chairman 30 May 2018 9:47AM $0.525 $0.270 fallen by 48.57%
- Appendix 3B & s708A Notice 24 May 2018 3:37PM $0.525 $0.270 fallen by 48.57%
- Trial ready Cannabis Sublingual Wafer Formulation complete 11 May 2018 9:32AM $0.425 $0.270 fallen by 36.47%
- Change of Auditor 1 May 2018 4:51PM $0.440 $0.270 fallen by 38.64%
- Cannabis Phase I Clinical Trial - Ethics Approval Received 1 May 2018 9:28AM $0.435 $0.270 fallen by 37.93%
- Quarterly Report and Appendix 4C 30 Apr 2018 5:32PM $0.435 $0.270 fallen by 37.93%
- Bod completes first order of medicinal cannabis oil 12 Apr 2018 9:12AM $0.440 $0.270 fallen by 38.64%
- Symbion to distribute Bod portfolio of natural medicines 9 Apr 2018 9:33AM $0.430 $0.270 fallen by 37.21%
- API to stock full Bod portfolio of natural medicines 5 Apr 2018 9:14AM $0.365 $0.270 fallen by 26.03%
- Bod Australia investor evening 27 Mar 2018 1:45PM $0.405 $0.270 fallen by 33.33%
- Bod completes import of first cannabis products 26 Mar 2018 12:09PM $0.360 $0.270 fallen by 25%
- Investor Presentation 2 Mar 2018 1:03PM $0.450 $0.270 fallen by 40%
- Bod delivers strong first half performance 27 Feb 2018 4:01PM $0.470 $0.270 fallen by 42.55%
- Half Yearly Report and Accounts 27 Feb 2018 4:01PM $0.470 $0.270 fallen by 42.55%
- Bods exclusive partner iX Biopharma secures China patent 26 Feb 2018 10:08AM $0.480 $0.270 fallen by 43.75%

176 - 200 of 284 results

Page 8 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.